The global cardiovascular devices market was valued at USD 53.67 billion in 2024 and is projected to reach USD 86.36 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.4% from 2025 to 2030. Cardiovascular disease (CVD) is one of the most widespread medical conditions globally.
In January 2024, the American Heart Association reported that CVD was the leading cause of death in the U.S., claiming 931,578 lives—more than the combined fatalities from all cancers and chronic respiratory diseases. Consequently, cardiovascular devices play a crucial role in accurately detecting and managing heart disorders, driving market growth. Key factors propelling this market include rapid technological advancements, the availability of affordable and effective devices, and a rising preference for minimally invasive procedures.
The increasing incidence of chronic cardiovascular disorders is significantly contributing to market expansion. Conditions such as heart attacks, coronary artery disease, and atrial fibrillation necessitate the use of cardiovascular devices, particularly coronary artery stents, which are vital for treating life-threatening cardiac issues. A May 2024 report from the WHO indicated that CVDs are the primary cause of disability and premature death in Europe, accounting for over 42.5% of annual deaths—approximately 10,000 daily. Notably, men are nearly 2.5 times more likely to die from CVDs than women, with individuals aged 30-69 in Eastern Europe and Central Asia facing a nearly fivefold higher risk compared to their Western European peers.
Over the past decade, advancements in cardiac device technologies and their applications have significantly improved treatment outcomes. Artificial intelligence has emerged as a pivotal development in cardiology, enhancing monitoring capabilities for specific heart conditions. For example, in May 2024, Medtronic announced the integration of AI into its Reveal Linq ICM devices in the U.S., Australia, and New Zealand, with plans for a European rollout by the end of 2024.
Key Market Trends & Insights
- Market Leadership in North America: North America dominated the cardiovascular devices market, accounting for 47.7% of the revenue share in 2024. This is driven by the increasing incidence of Atrial Fibrillation (AFib) and cardiovascular diseases, supportive government initiatives, and technological advancements. A February 2024 article in The Lancet Regional Health - Europe noted that AF is common, with a lifetime risk of approximately 1 in 3 to 5 individuals over the age of 45.
- Growth in the U.S. Market: The U.S. market is expected to grow substantially during the forecast period due to the rising number of CVD cases. An article from the American Heart Association published in January 2024 indicated that CVD results in about 2,552 deaths daily in the U.S., highlighting the urgent need for effective management and treatment options.
- Product Segment Insights: The surgical devices segment accounted for the largest revenue share of 68.8% in 2024. The diagnostics and monitoring devices segment is anticipated to experience the fastest CAGR of 9.6% during the forecast period, indicating a growing focus on diagnostic and monitoring solutions within the cardiovascular devices market.
Order a free sample PDF of the Carbon Accounting Software Market Intelligence Study, published by Grand View Research.
Market Size & Forecast
- 2024 Market Size: USD 53.67 Billion
- 2030 Projected Market Size: USD 86.36 Billion
- CAGR (2025-2030): 8.4%
- North America: Largest market in 2024
Key Companies & Market Share Insights
Market participants employ various strategies, including product launches, approvals, strategic acquisitions, and innovations, to enhance their global presence. In August 2024, GE HealthCare announced that its Vscan Air SL, a wireless handheld ultrasound system featuring Caption AI, received CE certification. This AI-driven technology facilitates rapid cardiac evaluations. Additionally, their Revolution Apex platform enables ECG-less cardiac CT scanning, allowing healthcare providers to capture cardiac images without requiring the patient's electrocardiogram.
Key Players
- ATI Abbott
- GE HealthCare
- Edwards Lifesciences Corporation
- W. L. Gore & Associates, Inc.
- Siemens Healthcare GmbH
- BIOTRONIK SE & Co. KG
- Canon Medical Systems Asia Pte. Ltd.
- B. Braun SE
- LivaNova PLC
- Cardinal Health
- Medtronic
- Boston Scientific Corporation
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion
The global cardiovascular devices market is set for significant growth, driven by the rising prevalence of cardiovascular diseases and ongoing technological advancements. As healthcare systems prioritize effective management of these conditions, the demand for innovative cardiovascular devices will continue to rise, offering substantial opportunities for companies in this sector. The integration of advanced technologies, such as artificial intelligence, is expected to further enhance treatment outcomes and monitoring capabilities, solidifying the importance of cardiovascular devices in modern healthcare.
